Data in brief 26 (2019) 104463

Cannabidibutol (CBDB), a novel butyl analog of cannabidiol, was identified as impurity of commercial cannabidiol (CBD) extracted from hemp (for full data and results interpretation see “Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog” Citti et al, 2019). The compound was isolated from a CBD sample and subject to a full characterization. First, a complete spectroscopic characterization was performed by Nuclear Magnetic Resonance (NMR): in particular, $^1$H-NMR, $^{13}$C-NMR, COSY, HSQC and HMBC, which were followed by UV absorption and circular dichroism (CD) spectra. In order to confirm the structural identity and stereochemistry of the compound, a stereoselective synthesis of the trans isomer ($^1$R,6$^R$) was carried out and all the chemical and spectroscopic properties were analyzed. The synthesized compound was characterized by NMR ($^1$H-NMR, $^{13}$C-NMR, COSY, HSQC and HMBC), Infra-Red spectroscopy (IR), UV and CD absorption, matching the results obtained for the natural isolated compound. With the analytical standard in hand, a simple high-performance liquid chromatography method coupled to UV detection (HPLC-UV) was developed and validated in house in terms of linearity, accuracy, precision, dilution integrity and stability. The present data might be useful to any researcher or
industry that may run into a very common impurity of CBD extracted from hemp, so it can be easily compared with their own experimental data.

© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

### Specifications Table

| Subject | Pharmaceutical Science |
|---------|------------------------|
| Specific subject area | Identification of an impurity in a sample of the drug cannabidiol (CBD), by synthesis and spectroscopic characterization, development and validation of an analytical method for its qualitative and quantitative determination |
| Type of data | Table |
| How data were acquired | NMR: DPX-600 Avance (Bruker) spectrometer (600.13 MHz for $^1$H NMR and 150.92 MHz for $^{13}$C NMR) equipped with a CryoProbe BBO H&F 5 mm, and processed with TopSpin v4.0.6 (Bruker BioSpin 2018) |
| IR: Perkin-Elmer Spectrum Two ATR-IR and processed with Spectrum 10™ software (PerkinElmer) |
| UV and Circular dichroism (CD): Jasco J-1100 spectropolarimeter |
| HPLC-UV: Agilent 1220 Infinity LC System (EZChrom software) |
| Data format | Raw and analyzed |
| Parameters for data collection | NMR spectra of compounds were acquired in CDCl$_3$ at 99.96% of deuteration. CD and UV spectra were acquired in acetonitrile (ACN) using quartz cells with a 10 mm path length. Optical rotation was measured in ACN, using a 1 mL–100 mm cell-length. All the measurements were performed at 298 K. HPLC separation was performed with a Poroshell 120 C18 column, eluting with 0.1% formic acid in water and ACN. |
| Description of data collection | NMR spectra were recorded using standard Bruker pulse programs. IR spectra were acquired in the range 450–4000 cm$^{-1}$. CD and UV spectra were acquired in the 400–200 nm range, using a 50 nm/ min scanning speed. HPLC-UV conditions were set as follows: isocratic elution with 70% B for 10 minutes, then 95% B pumped for 5 min and re-equilibration of the column for 2 min, flow rate maintained constant at 0.5 mL/min. Ibuprofen (1 µg/mL) was used as internal standard. The UV trace was acquired at 228 nm. |
| Data source location | NMR, IR, CD, UV: |
| City/Town/Region: Modena |
| Country: Italy |
| Latitude and longitude (and GPS coordinates): 44°37′54″N, 10°56′45″E |
| HPLC-UV: |
| City/Town/Region: Lecce |
| Country: Italy |
| Latitude and longitude (and GPS coordinates): 40°20′11″N, 18°07′15″E |
| Data accessibility | Raw data are accessible at the following link: https://drive.google.com/open?id=1gEL6bo5_btm5Gxul2FFvntxZKMLdlddN7 |
| Related research article | Author’s name: Cinzia Citti, Pasquale Linciano, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli, Aldo Lagana, Giuseppe Cannaza |
| Title: Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog |
| Journal: Journal of Pharmaceutical and Biomedical Analysis |
| https://doi.org/10.1016/j.jpba.2019.06.049 |

### Value of the Data

- Complete NMR, IR, UV and CD spectroscopic profile are available for researchers or industries that may run into the impurity CBDB in the drug substance CBD. The data provided herein may be easily comparable to their own experimental data for an unambiguous identification.
- CBD has entered the clinical field for the treatment of severe forms of infant epilepsy not responding to conventional therapies. The amount of the impurity CBDB may rise to relevant values when CBD is administered in high dose. Therefore, the HPLC-UV method will be of valuable help in determining this compound in other drug matrices.
- The data provided herein could be exploited in the near future for the identification of CBDB and other related cannabinoids in raw plant material, such as cannabis inflorescence for a comprehensive chemical profiling.
1. Data

Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog [1]. The following figures refer to the chemical characterization of CBDB obtained by stereoselective synthesis and CBDB isolated from authentic CBD samples.

Fig. 12 reports the superimposition of the Circular Dichroism (CD) spectra of isolated (green) and synthesized (blue) CBDB. The solvent used is acetonitrile, the path length is 1 cm and the concentration loaded is 10 μg/mL.

The following figures and tables refer to the validation of the HPLC-UV method for the quantification of CBDV and CBDB in samples of CBD.

Fig. 13 reports the HPLC-UV chromatograms of a blank sample (acetonitrile), an internal standard (IS) working solution, a standard mixture of cannabidivarin (CBDV) and cannabidibutol (CBDB) in IS working solution at the limit of detection (LOD, 0.10 μg/mL for CBDV and 0.04 μg/mL for CBDB), a standard mixture at the lower limit of quantification (LOQ, 0.28 μg/mL for CBDV and 0.12 μg/mL for CBDB), a standard mixture at three quality control (QC) levels, low (LQC, 0.56 μg/mL for CBDV and 0.24 μg/mL for CBDB), medium (MQC, 18.8 μg/mL for CBDV and 8.00 μg/mL for CBDB) and high (HQC, 45.1 μg/mL for CBDV and 19.2 μg/mL for CBDB), and an authentic cannabidiol (CBD) sample in IS working solution (the peak of CBD is not entirely visible as the chromatogram is zoomed in to highlight the impurities).

Table 1 reports the linearity parameters for CBDV and CBDB (slope, intercept, R² weighted, and linear range). Values are expressed as mean ± standard error (n = 3).

Table 1
Linearity parameters for CBDV and CBDB (slope, intercept and R² weighted). Values are expressed as mean ± standard error (n = 3).

| Compound | Slope ± SEM | Intercept ± SEM | R² (weighted) | Linear range (μg/mL) |
|----------|------------|----------------|--------------|----------------------|
| CBDV     | 0.294±0.002 | −0.001±0.002   | 0.9993       | 0.28−56.4             |
| CBDB     | 0.207±0.002 | −0.001±0.002   | 0.9989       | 0.12−24.0             |

Table 2 reports the intra-day and inter-day accuracy and precision of CBDV and CBDB at four concentration levels (LOD, LCQ, MQC and HQC). Values are expressed as mean of three analyses for intra-day accuracy and precision and 15 analyses for inter-day accuracy and precision (n = 3 for 5 consecutive days).

Table 2
Autosampler carryover calculated as percentage of the peak area of the analyte in a blank sample run after an HQC sample compared to the area of the analyte in the LLOQ sample.

| Compound | Carryover (%) |
|----------|--------------|
| CBDV     | 14.7 ± 3.8   |
| CBDB     | 15.8 ± 1.4   |
| IS       | <5           |

Table 3 shows the dilution integrity for CBDV and CBDB at three dilution factors (5, 10 and 20) calculated as accuracy and precision. Values are expressed as mean of five analyses (n = 5).

Table 4 relates to the stability data (bench-top and under refrigeration) for CBDV and CBDB calculated as mean of three analyses compared to nominal concentration of freshly prepared calibration curves.

Also, we have provided raw data files at this accessible link: https://drive.google.com/open?id=1gL6bo5_btm5GxulZFVnLxZKMLIdN7.

Where it is possible to find NMR FIDs for both synthetic and extracted cannabidibutol, HPLC-UV raw files with a blank sample, a sample at the LOD (limit of detection) concentration, a sample at the LOQ (limit of quantification) concentration, three samples at the QC levels (low, medium and high) and a
Table 3
Intra-day and inter-day accuracy and precision of CBDV and CBDB at four concentration levels (LLOQ, LCQ, MQC and HQC). Values are expressed as mean of three analyses for intra-day accuracy and precision and 15 analyses for inter-day accuracy and precision (n = 3 for 5 consecutive days).

|          | CBDV       |         | CBDB       |         |
|----------|------------|---------|------------|---------|
|          | Accuracy   | Precision | Accuracy   | Precision |
| Intra-day (n = 3) |  |  |  |  |
| LLOQ     | 102.1      | 1.38    | 101.0      | 1.62    |
| LCQ      | 98.23      | 2.25    | 105.5      | 12.0    |
| MQC      | 101.1      | 0.98    | 100.3      | 2.57    |
| HQC      | 104.9      | 1.09    | 103.0      | 3.71    |
| Inter-day (n = 15) |  |  |  |  |
| LLOQ     | 104.3      | 2.76    | 91.67      | 9.14    |
| LCQ      | 102.0      | 2.25    | 101.6      | 3.94    |
| MQC      | 109.0      | 0.96    | 102.0      | 2.37    |

Table 4
Dilution integrity for CBDV and CBDB at three dilution factors (5, 10 and 20) calculated as accuracy and precision. Values are expressed as mean of five analyses (n = 5).

| Dilution factor | CBDV |         | CBDB |         |
|-----------------|------|---------|------|---------|
|                 | Accuracy | CV    | Accuracy | CV    |
| 5               | 98.91       | 0.74  | 95.67       | 0.96  |
| 10              | 96.72       | 1.25  | 93.47       | 0.48  |
| 20              | 99.53       | 2.05  | 96.00       | 2.27  |

commercial CBD sample. Moreover, we have provided a GraphPad file with linearity data and an Excel file with the calculations for the method validation.

2. Experimental design, materials, and methods

2.1. NMR analyses

One-dimensional $^1$H and $^{13}$C NMR and two-dimensional NMR (COSY, HSQC and HMBC) were acquired on a DPX-600 Avance (Bruker) spectrometer (600.13 MHz for $^1$H NMR and 150.92 MHz for $^{13}$C NMR). A 10 mg aliquot of synthetic CBDB and 1 mg aliquot of CBDB isolated from CBD were solubilized in 700 and 250 µL of CDCl$_3$ (at 99.96% of deuteration) and placed in a 5 mm and 3 mm NMR tube, respectively. All NMR spectra were recorded at 298 K. All the NMR spectra were processed with TopSpin v4.0.6 (Bruker BioSpin 2018).

$^1$H-NMR spectra (Fig. 1a–c for synthetic CBDB and Fig. 7 for isolated CBDB), were acquired with a spectral width of 13204.2 Hz, a relaxation delay of 5 s, a pulse width of 11.23 Hz and 16 number of transient. Proton chemical shifts were reported in parts per million (ppm, δ units) and referenced to the solvent residual peaks (CDCl$_3$ δ = 7.26 ppm). Coupling constants are reported in Hertz (Hz). Splitting patterns are designed as s, singlet; d, doublet; t, triplet; q, quartet; dd, double doublet; m, multiplet; b, broad. $^{13}$C-NMR spectra (Fig. 2a–c for synthetic CBDB and Fig. 8 for isolated CBDB) were acquired with a spectral width of 33.3 kHz, a relaxation delay of 5 s, a pulse width of 10.00 Hz and 128 and 10240 number of transient for synthetic CBDB and extracted CBDB, respectively. Carbon chemical shifts were reported in parts per million (ppm, δ units) and referenced to the solvent residual peaks (CDCl$_3$ δ = 77.20 ppm). The COSY, shown in Figs. 4 and 10 for synthetic and isolated CBDB respectively, were recorded as a 1024 × 160 matrix with 2 transients per t1 increment and processed as a 1024 × 1024 matrix. The HSQC spectra, reported in Figs. 3 and 9 for synthetic and isolated CBDB respectively, were collected as a 1024 × 256 matrix with 4 transients per t1 increment.
Fig. 1. a: $^1$H-NMR of synthetic CBDB. b: $^1$H-NMR of synthetic CBDB from 3 to 5 ppm. c: $^1$H-NMR of synthetic CBDB from 0 to 3 ppm.
Fig. 2. a: $^{13}$C-NMR of synthetic CBDB. b: $^{13}$C-NMR of synthetic CBDB from 100 to 160 ppm. c: $^{13}$C-NMR of synthetic CBDB from 0 to 70 ppm.
and processed as a $1024 \times 1024$ matrix, and the one-bond heteronuclear coupling value was set to 145 Hz. The HMBC spectra, shown in Figs. 5 and 11 for synthetic and isolated CBDB respectively, were collected as a $2048 \times 220$ matrix with 8 transients per t1 increment and processed as a $2048 \times 1024$ matrix, and the long-range coupling value was set to 8 Hz. IR spectra, reported in Fig. 6 for synthetic CBDB, were recorded at 25 °C on a Perkin-Elmer Spectrum Two ATR-IR, scanning from 450 to 4000 cm$^{-1}$, and processed with Spectrum 10™ software (PerkinElmer). Circular dichroism (CD) and UV spectra (Fig. 12) were acquired on a Jasco (Tokyo, Japan) J-1100 spectropolarimeter using a 50 nm/min scanning speed. Quartz cells with a 10 mm path length were employed to record spectra in the 400-200 nm range.

2.2. HPLC-UV method validation

The chromatograms were acquired with the software EZChrom on an Agilent 1220 Infinity LC System (Waldbronn, Germany), consisting of a vacuum degasser, a binary pump, a manual injector, a column compartment and a UV detector. The separation of the analytes was performed with a Poroshell 120 C18 column (Poroshell 120 SB-C18, 3.0 × 150 mm, 2.7 μm, Agilent, Milan, Italy) eluting a mobile phase composed of 0.1% formic acid in both (A) water and (B) acetonitrile (ACN). The chromatographic conditions were set as follows: isocratic elution with 70% B for 10 minutes, then 95% B pumped for 5 min and re-equilibration of the column for 2 min for a total run time of 17 min. The flow rate was maintained constant at 0.5 mL/min. The loading loop capacity was 6 μL. The loop was washed.

Fig. 3. COSY of synthetic CBDB.
before each run first with 50 μL of ethanol 96% then with 50 μL of mobile phase. The UV trace was acquired at 228 nm. The analytes peaks were manually integrated using the EZChrom software (Agilent Technologies), which was employed also for controlling the online analysis.

Table 1 summarizes the experimental data obtained for testing linearity between the concentrations of CBDV and CBDB and the UV signal. Calibration curves were constructed at six non-zero calibration levels 0.28, 1.41, 2.82, 9.40, 28.2 and 56.4 μg/mL for CBDV, 0.12, 0.60, 1.20, 4.00, 12.0 and 24.0 μg/mL for CBDB, and 1.00 μg/mL for IS. Peak area ratios of analyte-to-IS (IS, ibuprofen 1 μg/mL) were plotted vs actual concentrations. Calibration curve was built at the beginning of each validation day of five consecutive days (n = 5). A linear correlation was assumed if the coefficient of determination (R²) was greater than 0.998 using weighed regression method (1/x²). The back calculated concentrations should be within 15% of the nominal concentrations, and within 20% of the lower limit of quantification (LLOQ).

Limit of detection (LOD) and limit of quantification (LOQ). Limit of detection (LOD) was estimated based on a 3:1 signal-to-noise (S/N) ratio. Standard stock solutions of the analytes were appropriately diluted at the levels of their respective estimated LOD values. The LOD values were then calculated as three times the standard deviation (SD) obtained by repeatedly analyzed standards (n = 5). Lower limit of quantification (LLOQ) was estimated based on a 10:1 S/N ratio and calculated as ten times the SD of
repeatedly analyzed standards. The upper limit of quantification (ULOQ) was set at 10% above the highest concentration of the analytes in a concentrated sample of CBD (10 mg/mL).

Table 2 reports the results of the evaluation of the autosampler carryover. Autosampler carryover was evaluated by running two blank samples after a calibration standard at the ULOQ and after a high concentration sample (CBD 10 mg/mL). The carryover should not be greater than 20% of the LOQ for the analytes and 5% for IS.

Table 3 reports the data of accuracy and precision. The precision and accuracy were evaluated at four levels, LLOQ (0.28 μg/mL for CBDV and 0.12 μg/mL for CBDB), LQC (0.56 μg/mL for CBDV and 0.24 μg/mL for CBDB), MQC (18.8 μg/mL for CBDV and 8.00 μg/mL for CBDB), and HQC (45.1 μg/mL for CBDV and 19.2 μg/mL for CBDB). Each sample was analyzed in triplicate within a single day to determine the intra-day precision and accuracy. The replicate analyses were repeated on freshly prepared standard solutions for five successive days (n = 15) to determine the inter-day precision and accuracy. The precision was expressed as coefficient of variation (CV), and the accuracy was expressed as the percentage of mean calculated compared to nominal concentration.

Table 4 shows the results of the dilution integrity experiments. Dilution integrity was carried out using a spiked standard solution of the analytes prepared by diluting standard stock solutions to a final concentration that is three times that of the ULOQ (170.4 μg/mL for CBDV and 72.00 μg/mL for CBDB). Dilution integrity was demonstrated by diluting the spiking solution in IS to 1/5, 1/10 and 1/20 of its
Fig. 6. IR of synthetic CBDB.

Fig. 7. $^1$H-NMR of isolated CBDB.
original concentration. Five replicates per dilution factor were run. The concentrations were calculated by applying the dilution factor 5, 10 and 20 against freshly prepared calibration curve. Dilution integrity is ensured as long as precision and accuracy are ≤15% and ±15% respectively.

Table 5 summarizes the stability tests. The short-term stability of the standard analytes was determined for LQC and HQC samples for 24 h at room temperature and under refrigeration (2–8 °C). Compounds were considered stable if the mean concentration (n = 3 for each sample) was within ±15% of the nominal concentration.

Table 5
Stability data (bench-top and under refrigeration) for CBDV and CBDB calculated as mean of three analyses compared to nominal concentration of freshly prepared calibration curves.

| Stability              | QC level | CBDV  | CBDB  |
|------------------------|----------|-------|-------|
| Bench-top (25 °C, 24 h)| LQC      | 96.72 | 103.1 |
|                        | HQC      | 104.5 | 101.5 |
| Refrigeration (2–8 °C, 24 h) | LQC   | 103.2 | 101.2 |
|                        | HQC      | 102.7 | 100.6 |

Fig. 8. 13C-NMR of isolated CBDB.
Fig. 9. COSY of isolated CBDB.
Fig. 10. HSQC of isolated CBDB.
Fig. 11. HMBC of isolated CBDB.

Fig. 12. Circular Dichroism (CD) of isolated (green) and synthesized (blue) CBDB. Solvent: acetonitrile, path length: 1 cm; concentration: 10 μg/mL.
Fig. 13. HPLC-UV chromatograms of a blank sample (acetonitrile), an internal standard (IS) working solution, a standard mixture of cannabidivarin (CBDV) and cannabidibutol (CBDB) in IS working solution at the limit of detection (LOD, 0.10 μg/mL for CBDV and 0.04 μg/mL for CBDB), a standard mixture at the lower limit of quantification (LLOQ, 0.28 μg/mL for CBDV and 0.12 μg/mL for CBDB), a standard mixture at three quality control (QC) levels, low (LQC, 0.56 μg/mL for CBDV and 0.24 μg/mL for CBDB), medium (MQC, 18.8 μg/mL for CBDV and 8.00 μg/mL for CBDB) and high (HQC, 45.1 μg/mL for CBDV and 19.2 μg/mL for CBDB), and an authentic cannabidiol (CBD) sample in IS working solution (the peak of CBD is not entirely visible as the chromatogram is zoomed in to highlight the impurities).
Acknowledgments

This work was supported by UNIHEMP research project “Use of Industrial Hemp biomass for Energy and new biochemicals Production” (ARS01_00668) funded by Fondo Europeo di Sviluppo Regionale (FESR) (within the PON R&I 2017–2020 – Axis 2 – Action II – OS 1.b). Grant decree UNIHEMP prot. n. 2016 of 27/07/2018; CUP B76C18000520005 – COR 571,294.

Also, this research work has been partly funded by the project “Development of a cannabis based galenical preparation” FONDO DI ATENEO PER LA RICERCA ANNO 2017 - FAR2017, Italy (A.006@FAR2017DIP@05FA-CANNAZZA_FAR2017-(.20) CUP E53C17000720005).

The authors would like to thank Boris Bañas of CBDepot (Prague, Czech Republic), RSM S.p.a. (Montale, Italy), Linnea SA (Riazzino, Switzerland), Crystal Hemp (Lugano, Switzerland), Farmacia Sant’Elia (Corato, Italy) and Farmacia Tundo Dr. Alfredo (Alliste, Italy) for providing authentic CBD samples.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] C. Citti, P. Linciano, F. Forni, M.A. Vandelli, G. Gigli, A. Laganà, G. Cannazza, Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog, J. Pharm. Biomed. Anal. 175 (2019) 112752. https://doi.org/10.1016/j.jpba.2019.06.049.